Clinical trials: Cystic Fibrosis (CF)
Cystic Fibrosis
Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
This study will determine the safety, tolerability, and pharmacokinetics of a single dose of GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.
- Trial name
- NCT01840735
- Testing
- GS-5737
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Gilead Sciences
Cystic Fibrosis
Increased Vitamin D Reduces Pulmonary Exacerbations in CF
The investigators study is designed to test the hypothesis that correction of vitamin D in CF patients can increase their lung function and decrease the number of their pulmonary exacerbations.
- Trial name
- NCT02043717
- Testing
- Vitamin D
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Hadassah Medical Organization
Cystic Fibrosis
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
The purpose of this study is to determine whether PUR118 is safe and tolerable in a population of subjects with Cystic Fibrosis.
- Trial name
- NCT01543191
- Testing
- PUR118
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Pulmatrix Inc.
Cystic Fibrosis
A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis
A double-blind, randomised study of OligoG DPI compared to placebo DPI, both on top of standard-of-care, to assess safety, efficacy and tolerability. Adult patients with Cystic Fibrosis will be included in the study.
- Trial name
- NCT03822455
- Testing
- OligoG DPI
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- AlgiPharma AS
Pancreatic Insufficiency, Cystic Fibrosis
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency.
- Trial name
- NCT03551691
- Testing
- Omeprazole 20mg Capsule
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Children's Hospital of Philadelphia
Cystic Fibrosis
Trikafta in Cystic Fibrosis Patients
This clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the…
- Trial name
- NCT03506061
- Testing
- Trikafta
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emory University
Diabetes, Cystic Fibrosis
Training in Shared Decision-making of Cystic Fibrosis Centers Competences in the Treatment of CF Related Diabetes in Adult Patients
Diabetes affects half of cystic fibrosis patients aged 30 years and older. It develops asymptomatically for a long time. Also, two options are possible: start insulin treatment now with the additional constraints associated with…
- Trial name
- FORAIDMUCO (NCT04891159)
- Testing
- Shared decision making
- Where
- 4 sites in France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis
Functional Respiratory Imaging and Orkambi in CF
Open-label study to investigate the effects of Orkambi in CF patients homozygous for the F508del mutation by functional respiratory imaging.
- Trial name
- NCT03956589
- Testing
- Orkambi
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- University Hospital, Antwerp
Cystic Fibrosis
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease.
- Trial name
- NCT02626182
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
Cavosonstat (N91115) is being studied as a potential novel therapy for cystic fibrosis (CF), and this study assesses a target population of patients who are heterozygous for F508del-CFTR and a gating mutation that is approved for…
- Trial name
- SNO-7 (NCT02724527)
- Testing
- Cavosonstat
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Nivalis Therapeutics, Inc.
Cystic Fibrosis, Chit1
Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients
Title: Duplication in Chitotriosidase (CHIT1) Gene and the Risk for Aspergillus Lung Disease in CF Patients. Aim: To evaluate the link between CHIT1 duplication in CF patients and the predisposition to ABPA or persistent…
- Trial name
- NCT01572870
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rambam Health Care Campus
Cystic Fibrosis
Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be…
- Trial name
- SIMPLIFY-HS (NCT06350461)
- Testing
- Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS)
- Where
- 81 sites in United States
- Volunteers
- 370 people
- Sponsor
- Nicole Hamblett
Cystic Fibrosis, Inflammation
Connexin Genotypes in Cystic Fibrosis
Background: There is wide variety in lung disease phenotype for the delta F508 (homozygous) genotype. A leukocyte driven inflammation is most important for the pathogenesis of pulmonary disease in CF.
- Trial name
- NCT04242420
- Testing
- Genotyping, Lung function, Microbiology
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 300 people
- Sponsor
- University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)
Non-cystic Fibrosis Bronchiectasis
Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
Bronchiectasis is a chronic lung disease of multiple aetiologies characterised by permanent dilatation of the calibre of a territory of the bronchial tree with impaired mucociliary clearance.
- Trial name
- Home-BRAC (NCT06487273)
- Testing
- SIMEOX, Remote Physiotherapy
- Where
- 57 sites in France, Germany and 4 more
- Volunteers
- 622 people
- Sponsor
- Physio-Assist
Cystic Fibrosis
Growth Hormone Therapy for Wasting in Cystic Fibrosis
Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to stimulate weight and muscle growth which will maximize nutritional potential and improve overall quality of life.
- Trial name
- NCT00803179
- Testing
- Nutropin AQ
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Massachusetts, Worcester
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)
The purpose of this study is to assess the safety and efficacy of Ultrase® MT20 compared to placebo for the correction of fat and protein malabsorption in participants with cystic fibrosis (CF) and exocrine pancreatic…
- Trial name
- NCT00408317
- Testing
- Ultrase® MT20
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Forest Laboratories
Fibrosing Colonopathy
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of…
- Trial name
- NCT01652157
- Testing
- ULTRESA, PANCREAZE, CREON
- Where
- 123 sites in United States
- Volunteers
- 17 people
- Sponsor
- AbbVie
Cystic Fibrosis
Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF)
The purpose of this research is to learn more about the heart and blood vessels in the lungs of people with cystic fibrosis (CF).
- Trial name
- NCT01860872
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cystic Fibrosis, Covid19
COVID-19 Antibody Responses in Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT04992234)
- Where
- 2 sites in Sweden
- Volunteers
- 113 people
- Sponsor
- Vastra Gotaland Region
Mucoviscidosis
Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)
Background The main risk factor for cervical cancer is the infection by human papillomavirus (HPV). Vaccination against HPV, offered to all girls aged 11 to 14 is an effective method of prevention against cervical pathology.
- Trial name
- NCT03653377
- Testing
- Self administrated questionnaire
- Where
- 7 sites in France
- Volunteers
- 81 people
- Sponsor
- Hospices Civils de Lyon